# NCT04724018 (NCT04724018)

> Sacituzumab Govitecan Plus EV in Metastatic UC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04724018
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Urothelial Cancer; Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Bladder Cancer
- Interventions: Sacituzumab Govitecan (SG); Enfortumab vedotin-ejfv (EV); Pembrolizumab
- Enrollment: 106
- Primary outcome: Maximum Tolerated Dose (MTD) of Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV) in Combination
- Primary outcome: Dose-limiting toxicity (DLT) of Sacituzumab Govitecan (SG) and Enfortumab Vedotin in combination
- Primary outcome: Efficacy of Sacituzumab Govitecan (SG) and Enfortumab Vedotin in combination
- Primary outcome: Efficacy of Sacituzumab Govitecan (SG) and Enfortumab Vedotin and Pembrolizumab in combination

## Commentary we found

- X threads: 16
- YouTube: 4
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct04724018

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04724018", "email": "<work email>"}; the inbox owner confirms by the emailed link.